An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
NCT04514367
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class
Conditions
Huntington Disease
Interventions
DRUG:
ANX005
Sponsor
Annexon, Inc.